What did we learn from Biogen's CMS slapdown? Data rule

The CMS decision to formally restrict coverage on Aduhelm decisively hammered home the last nail on the Alzheimer’s drug’s commercial coffin. But the muted impact …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

What did we learn from Biogen's CMS slapdown? Data rule

This article is available only to Premium subscribers

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

What did we learn from Bio­gen's CMS slap­down? Da­ta rule

This article is available only to Premium subscribers

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

What did we learn from Biogen's CMS slapdown? Data rule

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?